{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T19:49:14Z","timestamp":1786304954599,"version":"build-2736575974"},"reference-count":157,"publisher":"Elsevier","isbn-type":[{"value":"9780443134555","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.vh.2023.01.001","type":"book-chapter","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:08:40Z","timestamp":1692277720000},"page":"439-481","source":"Crossref","is-referenced-by-count":30,"title":["The androgen receptor"],"prefix":"10.1016","author":[{"given":"Greg","family":"Van-Duyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Moiseenkova-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Plymate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor M.","family":"Penning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0010","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0015","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bmcl.2011.01.010","article-title":"Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3)","volume":"21","author":"Adeniji","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1432-1033.2004.04395.x","article-title":"Androgen receptor function is modulated by the tissue-specific AR45 variant","volume":"272","author":"Ahrens-Fath","year":"2005","journal-title":"The FEBS Journal"},{"key":"10.1016\/bs.vh.2023.01.001_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.818891","article-title":"A comprehensive review of BET protein biochemistry, physiology, and pathological roles","volume":"13","author":"Ali","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: Clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0040","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of Taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncology"},{"issue":"19","key":"10.1016\/bs.vh.2023.01.001_bb0045","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice Variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2016.08.038","article-title":"Do patients with AR-V7-positive prostate cancer benefit from novel hormonal therapies? It all depends on definitions","volume":"71","author":"Antonarakis","year":"2017","journal-title":"European Urology"},{"key":"10.1016\/bs.vh.2023.01.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.012411","article-title":"Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer","volume":"296","author":"Asangani","year":"2021","journal-title":"The Journal of Biological Chemistry"},{"issue":"35","key":"10.1016\/bs.vh.2023.01.001_bb0065","doi-asserted-by":"crossref","first-page":"25801","DOI":"10.1074\/jbc.M703268200","article-title":"Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone","volume":"282","author":"Askew","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0070","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1074\/jbc.M114.610873","article-title":"The TRPM8 protein is a testosterone receptor: II. Functional evidence for an ionotropic effect of testosterone on TRPM8","volume":"290","author":"Asuthkar","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0075","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1074\/jbc.M114.610824","article-title":"The TRPM8 protein is a testosterone receptor: I. Biochemical evidence for direct TRPM8-testosterone interactions","volume":"290","author":"Asuthkar","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bju.14146","article-title":"Performance comparison of two androgen receptor splice variant 7 (AR-V7) detection methods","volume":"122","author":"Bernemann","year":"2018","journal-title":"BJU International"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0085","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1128\/MCB.19.12.8383","article-title":"The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1","volume":"19","author":"Bevan","year":"1999","journal-title":"Molecular and Cellular Biology"},{"issue":"17","key":"10.1016\/bs.vh.2023.01.001_bb0090","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","article-title":"Structural basis for antagonism and resistance of bicalutamide in prostate cancer","volume":"102","author":"Bohl","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"18","key":"10.1016\/bs.vh.2023.01.001_bb0095","doi-asserted-by":"crossref","first-page":"13648","DOI":"10.1074\/jbc.M611711200","article-title":"Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design","volume":"282","author":"Bohl","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0100","first-page":"1273","article-title":"Collocation of androgen receptor gene mutations in prostate cancer","volume":"7","author":"Buchanan","year":"2001","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","article-title":"SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder","volume":"142","author":"Cantagrel","year":"2010","journal-title":"Cell"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0115","doi-asserted-by":"crossref","first-page":"T199","DOI":"10.1530\/ERC-16-0298","article-title":"Emerging data on androgen receptor splice variants in prostate cancer","volume":"23","author":"Cao","year":"2016","journal-title":"Endocrine-Related Cancer"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1460-2075.1987.tb04763.x","article-title":"The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region","volume":"6","author":"Cato","year":"1987","journal-title":"The EMBO Journal"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0125","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1210\/me.2008-0017","article-title":"The contribution of different androgen receptor domains to receptor dimerization and signaling","volume":"22","author":"Centenera","year":"2008","journal-title":"Molecular Endocrinology"},{"issue":"4850","key":"10.1016\/bs.vh.2023.01.001_bb0130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/science.3353726","article-title":"Molecular cloning of human and rat complementary DNA encoding androgen receptors","volume":"240","author":"Chang","year":"1988","journal-title":"Science"},{"issue":"19","key":"10.1016\/bs.vh.2023.01.001_bb0135","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1073\/pnas.85.19.7211","article-title":"Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors","volume":"85","author":"Chang","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/bs.vh.2023.01.001_bb0140","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","article-title":"Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer","volume":"22","author":"Chen","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"38","key":"10.1016\/bs.vh.2023.01.001_bb0145","doi-asserted-by":"crossref","first-page":"25576","DOI":"10.1074\/jbc.M109.043133","article-title":"Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1","volume":"284","author":"Chen","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"10 Pt 1","key":"10.1016\/bs.vh.2023.01.001_bb0150","first-page":"1033","article-title":"Androgen receptor polymorphisms and the incidence of prostate cancer","volume":"11","author":"Chen","year":"2002","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"43","key":"10.1016\/bs.vh.2023.01.001_bb0155","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.vh.2023.01.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.06008","article-title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling","volume":"6","author":"Claessens","year":"2008","journal-title":"Nuclear Receptor Signaling"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: A novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0170","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/JOE-12-0238","article-title":"Regulation of the androgen receptor by post-translational modifications","volume":"215","author":"Coffey","year":"2012","journal-title":"The Journal of Endocrinology"},{"issue":"Pt 7","key":"10.1016\/bs.vh.2023.01.001_bb0175","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1242\/jcs.022103","article-title":"Structural basis for the nuclear import of the human androgen receptor","volume":"121","author":"Cutress","year":"2008","journal-title":"Journal of Cell Science"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0180","article-title":"Analyzing the androgen receptor interactome in prostate cancer: Implications for therapeutic intervention","volume":"11","author":"Dahiya","year":"2022","journal-title":"Cell"},{"issue":"38","key":"10.1016\/bs.vh.2023.01.001_bb0185","doi-asserted-by":"crossref","first-page":"26417","DOI":"10.1074\/jbc.M114.553818","article-title":"Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer","volume":"289","author":"Dalal","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","article-title":"The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial","volume":"2","author":"Dalton","year":"2011","journal-title":"Journal of Cachexia, Sarcopenia and Muscle"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1998.8209","article-title":"Discovery of nonsteroidal androgens","volume":"244","author":"Dalton","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/bs.vh.2023.01.001_bb0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsbmb.2016.04.016","article-title":"Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer","volume":"166","author":"Daniel","year":"2017","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"22","key":"10.1016\/bs.vh.2023.01.001_bb0205","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.jmb.2013.07.033","article-title":"Dissection of androgen receptor-promoter interactions: Steroid receptors partition their interaction energetics in parallel with their phylogenetic divergence","volume":"425","author":"De Angelis","year":"2013","journal-title":"Journal of Molecular Biology"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0210","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-11-0141","article-title":"Alternatively spliced androgen receptor variants","volume":"18","author":"Dehm","year":"2011","journal-title":"Endocrine-Related Cancer"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0215","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"TRANSFORMER: A randomized phase ii study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"1\u20133","key":"10.1016\/bs.vh.2023.01.001_bb0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0303-7207(92)90004-P","article-title":"Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene","volume":"88","author":"Deslypere","year":"1992","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/bs.vh.2023.01.001_bb0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41540-018-0064-1","article-title":"Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer","volume":"4","author":"Ebhardt","year":"2018","journal-title":"NPJ Systems Biology and Applications"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0230","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1038\/s41467-019-11594-y","article-title":"Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor","volume":"10","author":"Eftekharzadeh","year":"2019","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0235","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac104","article-title":"N\/C interactions are dispensable for normal in vivo functioning of the androgen receptor in male mice","volume":"163","author":"El Kharraz","year":"2022","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0240","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152764","article-title":"The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation","volume":"22","author":"El Kharraz","year":"2021","journal-title":"EMBO Reports"},{"issue":"4854","key":"10.1016\/bs.vh.2023.01.001_bb0245","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","article-title":"The steroid and thyroid hormone receptor superfamily","volume":"240","author":"Evans","year":"1988","journal-title":"Science"},{"issue":"7","key":"10.1016\/bs.vh.2023.01.001_bb0250","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1074\/mcp.M400021-MCP200","article-title":"Quantitative cancer proteomics: Stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research","volume":"3","author":"Everley","year":"2004","journal-title":"Molecular & Cellular Proteomics"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0255","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.biopha.2006.07.082","article-title":"Post-translational modifications of steroid receptors","volume":"60","author":"Faus","year":"2006","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"10","key":"10.1016\/bs.vh.2023.01.001_bb0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"The Lancet Oncology"},{"issue":"32","key":"10.1016\/bs.vh.2023.01.001_bb0265","doi-asserted-by":"crossref","first-page":"29304","DOI":"10.1074\/jbc.M204131200","article-title":"Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites","volume":"277","author":"Gioeli","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0270","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/jhg.2016.49","article-title":"Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men","volume":"61","author":"Gomez","year":"2016","journal-title":"Journal of Human Genetics"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0275","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/jme.0.0270309","article-title":"The putative androgen receptor-A form results from in vitro proteolysis","volume":"27","author":"Gregory","year":"2001","journal-title":"Journal of Molecular Endocrinology"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0280","doi-asserted-by":"crossref","first-page":"17043","DOI":"10.1038\/s41598-018-35346-y","article-title":"Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes","volume":"8","author":"Guo","year":"2018","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0285","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1021\/acs.analchem.7b04590","article-title":"Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich's ataxia","volume":"90","author":"Guo","year":"2018","journal-title":"Analytical Chemistry"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0290","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1093\/nar\/16.12.5263","article-title":"Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus","volume":"16","author":"Ham","year":"1988","journal-title":"Nucleic Acids Research"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0295","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"issue":"52","key":"10.1016\/bs.vh.2023.01.001_bb0300","doi-asserted-by":"crossref","first-page":"37219","DOI":"10.1074\/jbc.274.52.37219","article-title":"Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain","volume":"274","author":"He","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"issue":"30","key":"10.1016\/bs.vh.2023.01.001_bb0305","doi-asserted-by":"crossref","first-page":"22986","DOI":"10.1074\/jbc.M002807200","article-title":"FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor","volume":"275","author":"He","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.vh.2023.01.001_bb7505","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nature Communications"},{"issue":"18","key":"10.1016\/bs.vh.2023.01.001_bb0310","first-page":"5111","article-title":"Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China","volume":"60","author":"Hsing","year":"2000","journal-title":"Cancer Research"},{"key":"10.1016\/bs.vh.2023.01.001_bb0315","first-page":"1163","article-title":"Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference","volume":"25","author":"Huggins","year":"1965","journal-title":"Cancer Research"},{"key":"10.1016\/bs.vh.2023.01.001_bb0320","first-page":"293","article-title":"Studies on prostatic cancer 1. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Research"},{"key":"10.1016\/bs.vh.2023.01.001_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2020.100186","article-title":"Antibody selection influences the detection of AR-V7 in primary prostate cancer","volume":"24","author":"Kaczorowski","year":"2020","journal-title":"Cancer Treatment and Research Communications"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082092","article-title":"Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer","volume":"12","author":"Kafka","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0335","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-018-0172-0","article-title":"Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases","volume":"119","author":"Kallio","year":"2018","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0340","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1530\/JME-18-0150","article-title":"Applying mass spectrometric methods to study androgen biosynthesis and metabolism in prostate cancer","volume":"62","author":"Knuuttila","year":"2019","journal-title":"Journal of Molecular Endocrinology"},{"key":"10.1016\/bs.vh.2023.01.001_bb0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fendo.2017.00002","article-title":"Non-genomic actions of the androgen receptor in prostate cancer","volume":"8","author":"Leung","year":"2017","journal-title":"Frontiers in Endocrinology"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0350","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0355","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10822-016-9992-2","article-title":"Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation","volume":"30","author":"Liu","year":"2016","journal-title":"Journal of Computer-Aided Molecular Design"},{"issue":"24","key":"10.1016\/bs.vh.2023.01.001_bb0360","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/bs.vh.2023.01.001_bb792","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","article-title":"AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0365","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41391-020-0217-3","article-title":"Androgen receptor variant-driven prostate cancer. II: Advances in laboratory investigations","volume":"23","author":"Lu","year":"2020","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0370","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1210\/mend-2-12-1265","article-title":"The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate","volume":"2","author":"Lubahn","year":"1988","journal-title":"Molecular Endocrinology"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0375","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eururo.2017.11.038","article-title":"Role of androgen receptor variants in prostate cancer: Report from the 2017 mission androgen receptor variants meeting","volume":"73","author":"Luo","year":"2018","journal-title":"European Urology"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0380","article-title":"Androgen receptor and its splicing variant 7 expression in peripheral blood mononuclear cells and in circulating tumor cells in metastatic castration-resistant prostate cancer","volume":"9","author":"Marin-Aguilera","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0385","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.18632\/oncotarget.3550","article-title":"Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer","volume":"6","author":"Marin-Aguilera","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0390","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor N-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"Investigational New Drugs"},{"key":"10.1016\/bs.vh.2023.01.001_bb0395","doi-asserted-by":"crossref","first-page":"14388","DOI":"10.1038\/ncomms14388","article-title":"Structure of the homodimeric androgen receptor ligand-binding domain","volume":"8","author":"Nadal","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.vh.2023.01.001_bb0400","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.mce.2017.06.013","article-title":"Development of selective androgen receptor modulators (SARMs)","volume":"465","author":"Narayanan","year":"2018","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0405","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.96.5.1858","article-title":"Proteasome-dependent degradation of the human estrogen receptor","volume":"96","author":"Nawaz","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/bs.vh.2023.01.001_bb0410","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/aje\/155.10.883","article-title":"Androgen receptor CAG repeats and prostate cancer","volume":"155","author":"Nelson","year":"2002","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0415","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1471-4159.2011.07438.x","article-title":"Steroid receptor coactivator 2 modulates steroid-dependent male sexual behavior and neuroplasticity in Japanese quail (Coturnix japonica)","volume":"119","author":"Niessen","year":"2011","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0420","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/pr0255708","article-title":"Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC)","volume":"2","author":"Ong","year":"2003","journal-title":"Journal of Proteome Research"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0425","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-018-0085-0","article-title":"Alternative splicing in prostate cancer","volume":"15","author":"Paschalis","year":"2018","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0430","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","article-title":"JMJD6 is a druggable oxygenase that regulates AR-V7 expression in prostate cancer","volume":"81","author":"Paschalis","year":"2021","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0435","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1110\/ps.051905906","article-title":"Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity","volume":"15","author":"Pereira de J\u00e9sus-Tran","year":"2006","journal-title":"Protein Science"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0440","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0002-9343(77)90313-8","article-title":"Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency","volume":"62","author":"Peterson","year":"1977","journal-title":"The American Journal of Medicine"},{"issue":"25","key":"10.1016\/bs.vh.2023.01.001_bb0445","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007258","article-title":"Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis","volume":"96","author":"Qin","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0450","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","article-title":"Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer","volume":"23","author":"Qu","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.vh.2023.01.001_bb0455","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/ncomms2912","article-title":"Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer","volume":"4","author":"Ravindranathan","year":"2013","journal-title":"Nature Communications"},{"issue":"50","key":"10.1016\/bs.vh.2023.01.001_bb0460","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/onc.2013.508","article-title":"Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype","volume":"33","author":"Robinson","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0465","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.vh.2023.01.001_bb0470","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","article-title":"Steroid 5 alpha-reductase: Two genes\/two enzymes","volume":"63","author":"Russell","year":"1994","journal-title":"Annual Review of Biochemistry"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0475","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1073\/pnas.081565498","article-title":"Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone","volume":"98","author":"Sack","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.vh.2023.01.001_bb0480","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42003-018-0105-8","article-title":"Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance","volume":"1","author":"Salami","year":"2018","journal-title":"Communications Biology"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0485","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0361-090X(03)00106-5","article-title":"Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population","volume":"27","author":"Santos","year":"2003","journal-title":"Cancer Detection and Prevention"},{"key":"10.1016\/bs.vh.2023.01.001_bb7500","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0490","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","article-title":"Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer","volume":"4","author":"Scher","year":"2018","journal-title":"JAMA Oncology"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0495","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncology"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0500","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/clinchem\/hvaa220","article-title":"Quantification of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 protein expression in bone biopsies by targeted mass spectrometry without acid decalcification","volume":"66","author":"Schoenherr","year":"2020","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.vh.2023.01.001_bb0505","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.steroids.2017.10.018","article-title":"N-terminal truncations in sex steroid receptors and rapid steroid actions","volume":"133","author":"Schreihofer","year":"2018","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0510","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.eururo.2017.07.024","article-title":"AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: Association with treatment-specific outcome under abiraterone and enzalutamide","volume":"72","author":"Seitz","year":"2017","journal-title":"European Urology"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0515","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0520","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","article-title":"Darolutamide (ODM-201) for the treatment of prostate cancer","volume":"18","author":"Shore","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0525","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/sj.pcan.4500967","article-title":"Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues","volume":"10","author":"Sircar","year":"2007","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"17","key":"10.1016\/bs.vh.2023.01.001_bb0530","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1073\/pnas.93.17.8884","article-title":"CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription","volume":"93","author":"Smith","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"16","key":"10.1016\/bs.vh.2023.01.001_bb0535","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-22-0851","article-title":"Assessment of androgen receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer","volume":"28","author":"Sowalsky","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0540","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","article-title":"The link between androgen receptor splice variants and castration-resistant prostate cancer","volume":"5","author":"Sprenger","year":"2014","journal-title":"Hormones and Cancer"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0545","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2017.330","article-title":"Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis","volume":"37","author":"Stelloo","year":"2018","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/bs.vh.2023.01.001_bb0550","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0555","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0560","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: A phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"European Urology"},{"issue":"21","key":"10.1016\/bs.vh.2023.01.001_bb0565","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.vh.2023.01.001_bb0570","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jms.1438","article-title":"Mass spectrometry of selective androgen receptor modulators","volume":"43","author":"Thevis","year":"2008","journal-title":"Journal of Mass Spectrometry"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0575","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1073\/pnas.86.1.327","article-title":"Characterization and expression of a cDNA encoding the human androgen receptor","volume":"86","author":"Tilley","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0580","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pros.22745","article-title":"5alpha-reductase type 3 enzyme in benign and malignant prostate","volume":"74","author":"Titus","year":"2014","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/bs.vh.2023.01.001_bb0585","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Titus","year":"2005","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0590","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0006-291X(88)81214-2","article-title":"Cloning, structure and expression of a cDNA encoding the human androgen receptor","volume":"153","author":"Trapman","year":"1988","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0595","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1210\/mend.14.8.0497","article-title":"Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells","volume":"14","author":"Tyagi","year":"2000","journal-title":"Molecular Endocrinology"},{"issue":"41","key":"10.1016\/bs.vh.2023.01.001_bb0600","doi-asserted-by":"crossref","first-page":"38087","DOI":"10.1074\/jbc.M203313200","article-title":"Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells","volume":"277","author":"Ueda","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0605","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","article-title":"Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer","volume":"99","author":"Uemura","year":"2008","journal-title":"Cancer Science"},{"issue":"Pt 8","key":"10.1016\/bs.vh.2023.01.001_bb0610","first-page":"1970","article-title":"Stepwise androgen receptor dimerization","volume":"125","author":"van Royen","year":"2012","journal-title":"Journal of Cell Science"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0615","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0620","first-page":"228","article-title":"New approaches to targeting the androgen receptor pathway in prostate cancer","volume":"19","author":"Velho","year":"2021","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"1\u20132","key":"10.1016\/bs.vh.2023.01.001_bb0625","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.mce.2013.05.004","article-title":"Expression and characterization of androgen receptor coregulators, SRC-2 and HBO1, during human testis ontogenesis and in androgen signaling deficient patients","volume":"375","author":"Vija","year":"2013","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0630","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nature Genetics"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0635","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00345-018-02619-0","article-title":"Role of androgen receptor splice variants, their clinical relevance and treatment options","volume":"38","author":"Wach","year":"2020","journal-title":"World Journal of Urology"},{"issue":"8","key":"10.1016\/bs.vh.2023.01.001_bb0640","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/(SICI)1096-9888(199908)34:8<885::AID-JMS846>3.0.CO;2-U","article-title":"Measurement of polymorphic trinucleotide repeats in the androgen receptor gene by matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"34","author":"Wada","year":"1999","journal-title":"Journal of Mass Spectrometry"},{"issue":"2","key":"10.1016\/bs.vh.2023.01.001_bb0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192779","article-title":"Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/bs.vh.2023.01.001_bb0650","article-title":"Simultaneous quantification of mitochondrial mature frataxin and extra-mitochondrial frataxin isoform E in Friedreich's ataxia blood","volume":"16","author":"Wang","year":"2022","journal-title":"Frontiers in Neuroscience"},{"issue":"17","key":"10.1016\/bs.vh.2023.01.001_bb0655","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1074\/jbc.M400970200","article-title":"Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells","volume":"279","author":"Wang","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.vh.2023.01.001_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.01.001","article-title":"A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics","volume":"192","author":"Wangtrakuldee","year":"2019","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"11","key":"10.1016\/bs.vh.2023.01.001_bb0665","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.molcel.2022.03.035","article-title":"Allosteric interactions prime androgen receptor dimerization and activation","volume":"82","author":"Wasmuth","year":"2022","journal-title":"Molecular Cell"},{"issue":"15","key":"10.1016\/bs.vh.2023.01.001_bb0670","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1073\/pnas.1922159117","article-title":"Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG","volume":"117","author":"Wasmuth","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0675","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nature Reviews. Cancer"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0680","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","article-title":"Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer","volume":"70","author":"Welti","year":"2016","journal-title":"European Urology"},{"issue":"13","key":"10.1016\/bs.vh.2023.01.001_bb0685","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"10.1016\/bs.vh.2023.01.001_bb0690","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1021\/acs.analchem.8b01175","article-title":"Quantification of serum high mobility group box 1 by liquid chromatography\/high-resolution mass spectrometry: Implications for its role in immunity, inflammation, and cancer","volume":"90","author":"Weng","year":"2018","journal-title":"Analytical Chemistry"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0695","doi-asserted-by":"crossref","first-page":"15788","DOI":"10.1038\/s41598-020-72884-w","article-title":"Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich's ataxia","volume":"10","author":"Weng","year":"2020","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0700","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1073\/pnas.91.4.1234","article-title":"A and B forms of the androgen receptor are present in human genital skin fibroblasts","volume":"91","author":"Wilson","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.vh.2023.01.001_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114119","article-title":"Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)","volume":"230","author":"Xie","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/bs.vh.2023.01.001_bb0710","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc2695","article-title":"Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family","volume":"9","author":"Xu","year":"2009","journal-title":"Nature Reviews. Cancer"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0715","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1021\/pr050175d","article-title":"Analysis of protein expression during oxidative stress in breast epithelial cells using a stable isotope labeled proteome internal standard","volume":"4","author":"Yan","year":"2005","journal-title":"Journal of Proteome Research"},{"issue":"21","key":"10.1016\/bs.vh.2023.01.001_bb0720","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.18632\/oncotarget.2536","article-title":"Stromal TGF-beta signaling induces AR activation in prostate cancer","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"issue":"41","key":"10.1016\/bs.vh.2023.01.001_bb0725","doi-asserted-by":"crossref","first-page":"36152","DOI":"10.1074\/jbc.M111.265124","article-title":"Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells","volume":"286","author":"Yang","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"issue":"20","key":"10.1016\/bs.vh.2023.01.001_bb0730","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1158\/1078-0432.CCR-13-1151","article-title":"Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth","volume":"19","author":"Yepuru","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/bs.vh.2023.01.001_bb0735","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molcel.2015.01.025","article-title":"Structure of a biologically active estrogen receptor-coactivator complex on DNA","volume":"57","author":"Yi","year":"2015","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0740","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/jpet.102.040840","article-title":"Pharmacodynamics of selective androgen receptor modulators","volume":"304","author":"Yin","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"10.1016\/bs.vh.2023.01.001_bb0745","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1055-9965.EPI-14-0020","article-title":"Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer","volume":"23","author":"Yoo","year":"2014","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"15","key":"10.1016\/bs.vh.2023.01.001_bb0750","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1158\/1078-0432.CCR-14-0292","article-title":"Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor","volume":"20","author":"Yu","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/bs.vh.2023.01.001_bb0755","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.molcel.2020.06.031","article-title":"Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes","volume":"79","author":"Yu","year":"2020","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/bs.vh.2023.01.001_bb0760","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1541-7786.MCR-16-0236","article-title":"Interplay between cytoplasmic and nuclear androgen receptor splice variants mediates castration resistance","volume":"15","author":"Zhan","year":"2017","journal-title":"Molecular Cancer Research"},{"issue":"3","key":"10.1016\/bs.vh.2023.01.001_bb0765","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1006\/bbrc.2001.5030","article-title":"Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry","volume":"284","author":"Zhu","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"36","key":"10.1016\/bs.vh.2023.01.001_bb0770","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1021\/bi010525j","article-title":"Mass spectrometric characterization of the human androgen receptor ligand-binding domain expressed in Escherichia coli","volume":"40","author":"Zhu","year":"2001","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/bs.vh.2023.01.001_bb0775","first-page":"389","article-title":"Structural determinants of DNA-binding specificity by steroid receptors","volume":"9","author":"Zilliacus","year":"1995","journal-title":"Molecular Endocrinology"}],"container-title":["Vitamins and Hormones","Hormone Receptors: Structures and Functions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672923000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672923000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T05:51:12Z","timestamp":1702965072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672923000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443134555"],"references-count":157,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2023.01.001","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}